Fulgent Genetics, Inc. (FLGT) released Loss for fourth quarter of -$5.888 million
The company's bottom line came in at -$5.888 million, or -$0.19 per share. This compares with -$128.149 million, or -$4.30 per share, last year.
The company's revenue for the period rose 8.1% to $76.214 million from $70.505 million last year.
Fulgent Genetics, Inc. earnings at a glance (GAAP) :
-Earnings: -$5.888 Mln. vs. -$128.149 Mln. last year.-EPS: -$0.19 vs. -$4.30 last year.-Revenue: $76.214 Mln vs. $70.505 Mln last year.
Excluding items, for the fourth quarter, the company recorded a profit of $1.163 million, or $0.04 per share, lesser than $8.269 million, or $0.28 per share, posted for the same period last year.
Looking ahead, for the full-year 2025, the company expects a wider net loss. However, it anticipates an increase in core revenue.
Fulgent expects a net loss of 1.95 per share, with an adjusted loss of around $0.65 per share. On average, three analysts polled expect the firm to report a loss of $0.46 per share for the year. Analysts’ estimates typically exclude special items.
Annual core revenue is expected to be around $310 million, below analysts’ forecast of $324.21 million.
For the full-year 2024, the company has recorded a net loss per share of $1.41 per share, with adjusted earnings per share of $0.49, on core revenue of $281.2 million.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.